Dataset Information


Glioblastoma Recurrence and the Role of O6-Methylguanine-DNA Methyltransferase Promoter Methylation.

ABSTRACT: Tumor recurrence in glioblastoma multiforme (GBM) is often attributed to acquired resistance to the standard chemotherapeutic agent, temozolomide (TMZ). Promoter methylation of the DNA repair gene MGMT (O6-methylguanine-DNA methyltransferase) has been associated with sensitivity to TMZ, whereas increased expression of MGMT has been associated with TMZ resistance. Clinical studies have observed a downward shift in MGMT methylation percentage from primary to recurrent stage tumors; however, the evolutionary processes that drive this shift and more generally the emergence and growth of TMZ-resistant tumor subpopulations are still poorly understood. Here, we develop a mathematical model, parameterized using clinical and experimental data, to investigate the role of MGMT methylation in TMZ resistance during the standard treatment regimen for GBM-surgery, chemotherapy, and radiation. We first found that the observed downward shift in MGMT promoter methylation status between detection and recurrence cannot be explained solely by evolutionary selection. Next, our model suggests that TMZ has an inhibitory effect on maintenance methylation of MGMT after cell division. Finally, incorporating this inhibitory effect, we study the optimal number of TMZ doses per adjuvant cycle for patients with GBM with high and low levels of MGMT methylation at diagnosis.


PROVIDER: S-EPMC6732255 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | S-EPMC3397507 | BioStudies
2018-01-01 | S-EPMC5873285 | BioStudies
2009-01-01 | S-EPMC2773462 | BioStudies
1000-01-01 | S-EPMC6026589 | BioStudies
2013-01-01 | S-EPMC4648381 | BioStudies
2020-01-01 | S-EPMC7428254 | BioStudies
2020-01-01 | S-EPMC7441403 | BioStudies
2019-01-01 | S-EPMC6773736 | BioStudies
2019-01-01 | S-EPMC6872666 | BioStudies
1000-01-01 | S-EPMC3248301 | BioStudies